NEW YORK (GenomeWeb) – SeraCare Life Sciences and Toma Biosciences announced today that they are entering into a codevelopment partnership.

Terms of the agreement call for SeraCare to provide Toma with access to its Seraseq Solid Tumor Mutation mix reference material technology to support the development and validation of Toma OS-Seq, a comprehensive solid tumor gene analysis kit, and Toma's upcoming PlasmaSeq liquid biopsy test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.